Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice

Atherosclerosis. 2009 Sep;206(1):54-60. doi: 10.1016/j.atherosclerosis.2009.01.039. Epub 2009 Feb 7.

Abstract

Objectives and background: Recent evidence has revealed that aldosterone (ALDO) is produced in the vasculature, and acts directly in the cardiovascular system. This study was designed to examine the role of ALDO in the process of long-term renin-angiotensin system (RAS) induced vascular remodeling.

Material and method: Hypertensive transgenic mice that overproduce angiotensin II (AngII), i.e., Tsukuba-Hypertensive-Mice (THM), were given tap water or 1% salt water and treated with or without Spironolactone (SPRL: 20mg/kg/day) for 4 weeks. We also employed A7r5 cells and investigated the effect of SPRL on the AngII mediated signal transduction in the vascular smooth muscle cells.

Results: Intimal hyperplasia, medial hypertrophy and degradation of medial elastic laminae were observed in the abdominal aorta, independent of blood pressure. Taking 1% salt water markedly enhanced these changes. In contrast, SPRL-treated THM showed almost complete disappearance of these intimal hyperplasia and medial hypertrophy. Osteopontin (OPN) was markedly up-regulated in the intima and media. However, it was inhibited by SPRL treatment in spite of high level of AngII. In A7r5 cells, AngII (10(-7)muM) induced OPN expression and pretreatment with MEK, PI3K, and EGFR inhibitor suppressed it. SPRL pretreatment also inhibited AngII-induced ERK and AKT phosphorylation, and resulted in the suppression of AngII-induced OPN expression.

Conclusions: ALDO blockade by SPRL restores the vascular remodeling caused by the long-term RAS enhancement even in the high level of AngII, independent of blood pressure. Blocking AngII alone may not be sufficient, and direct ALDO blockade is also important to prevent vascular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone / physiology*
  • Angiotensin II / metabolism*
  • Animals
  • Female
  • Hyperplasia / drug therapy
  • Hyperplasia / metabolism
  • Hyperplasia / pathology
  • Hypertension / physiopathology
  • Hypertrophy / metabolism
  • Male
  • Mice
  • Mice, Transgenic
  • Mineralocorticoid Receptor Antagonists / pharmacology*
  • Osteopontin / metabolism
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology
  • Spironolactone / therapeutic use*
  • Tunica Intima / pathology

Substances

  • Mineralocorticoid Receptor Antagonists
  • Osteopontin
  • Angiotensin II
  • Spironolactone
  • Aldosterone